The goal of this study was to identify, in advanced NSCLC patients with PD-L1 ≥ 50% and no EGFR/ALK aberration, which baseline features could predict a patient’s future disease progression assessed radiographically at the first follow-up CT. This evidence concerns the gene ALK and non-small cell lung carcinoma.